15^th World Congress on
Hematology and Oncology

Sergey Suchkov was born in the City of Astrakhan, Russia. In 1980, graduated from Astrakhan State Medical University and was awarded MD. In 1985, maintained his PhD at the I.M. Sechenov Moscow Medical Academy and Inst of Med Enzymology. In 2001, and then his Doctor Degree at the Nat Inst of Immunology in Russia. From 1989 through 1995, was the Head of the Lab of Clin Immunology, Helmholtz Eye Research Inst in Moscow. From 1995 through 2004 - a Chair of the Dept for Clin Immunology, Moscow Clin Research Institute (MONIKI). In 1993-1996, was a Secre-tary-in-Chief of the Editorial Board, of Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK.

Translational Medicine

Luca Roncati, Italian pathologist, physician-scientist, anti-cancer patent inventor, academic editor, medical lecturer, and award-winning author with more than 250 publications to his credit, specialized in gynecologic oncology, pediatric pathology, hematopathology and soft tissue tumors, eponym of Roncati-Manenti triad, describer of T rex lymphoma, pioneering researcher in COVID-19, leading researcher in nanopathology, forensics expert and adjunct professor of anatomical pathology at the University of Modena and Reggio Emilia (Italy).

Surgical pathology; Oncology; Hematopathology; Oncohematology; Lymphoma; Gynecologic pathology; Gynecologic oncology; Breast cancer; Epstein-Barr virus (EBV); Kaposi's sarcoma-associated herpesvirus (HHV8); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Coronavirus disease 2019 (COVID-19); Human papilloma virus (HPV); HPV test; PAP smear; Nanopathology; Anatomical pathology; Forensic sciences.

Stefan Gluck, MD, PhD, FRCPC is a medical oncologist (fully licensed in the state of FL) and is currently a freelance consultant for oncology hematology immunology and biotech companies. He was V.P. Global Medical Affairs, at Celgene Corporation from October 2014 until December 2019. He oversaw oncology activities worldwide, as well as the ImmuneOncology program in solid tumors and hematology. He contributed to activities of Celgene around Early Assets and was prat of the very successful BD team. In early 2020, after Celgene was acquired by BMS, and when the pandemic hit, he joined remotely REGENERON as VP and Franchise Head, Global Medical Affairs, Oncology - Hematology until July 2021. During these 16 months at GMA, he built a team of 27 colleagues virtually and actually never met anyone in person. At present, his focus is on helping small companies to get their innovative products to patients, hopefully prolonging, improving their lives and potentially lead the efforts to cures of cancer for many. He previously served as a Sylvester Professor in the Department of Medicine at Miller School of Medicine, University of Miami, Florida until September 2014. From 2003–2008, he was the Clinical Director of the Braman Family Breast Cancer Institute at UM. His clinical practise focussed on patients with breast cancer and during his hospital service, all malignant diseases including hematology and solid tumors. He enjoyed to teach fellows, residents, and medical MD/PhD students in hematology and oncology, bedside and in class courses. He has authored or co-authored over 275 articles. In addition, Dr Glück has written or co-written several book chapters, numerous abstracts and has presented more than 500 papers at national and international meetings. Additionally, he was very active with the following companies as an independent scientific and medical advisor for oncology efforts, including Agendia, Amgen, Pfizer, Novartis, Roche/Genentech, GSK, and Eli Lilly

His clinical practise focussed on patients with breast cancer and during his hospital service, all malignant diseases including hematology and solid tumors. Oncology focus on solid tumors and target / bio/immunotherapy. clin dev and med affairs, IND, Phase 1 and FIH - and biomarkers for those; Breast ca; upper GI; Gyne cancers; H&N and lung cancer.